Black Rock Inc. Plus Therapeutics, Inc. Transaction History

Black Rock Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.46 - $1.02 $19,385 - $42,984	-42,142 Reduced 28.75%	104,427 $56,000
Q1 2022 May 12, 2022	BUY	$0.87 - $1.32 $15,138 - $22,969	17,401 Added 13.47%	146,569 $146,000
Q4 2021 Feb 10, 2022	BUY	$1.03 - $1.94 $870 - $1,639	845 Added 0.66%	129,168 $136,000
Q3 2021 Nov 09, 2021	SELL	$1.83 - $2.46 $57,712 - $77,581	-31,537 Reduced 19.73%	128,323 $245,000
Q2 2021 Aug 11, 2021	BUY	$2.0 - $2.89 $319,720 - $461,995	159,860 New	159,860 $410,000

Ticker PSTV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,601,400
Market Cap $36.6M
Description
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, lep...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.